MX2016000381A - Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1. - Google Patents
Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1.Info
- Publication number
- MX2016000381A MX2016000381A MX2016000381A MX2016000381A MX2016000381A MX 2016000381 A MX2016000381 A MX 2016000381A MX 2016000381 A MX2016000381 A MX 2016000381A MX 2016000381 A MX2016000381 A MX 2016000381A MX 2016000381 A MX2016000381 A MX 2016000381A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- virus
- particle
- ligand
- kit
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 108010087302 Viral Structural Proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona una partícula de tipo viral que comprende una proteína estructural viral y un antígeno derivado de PD-1 o un ligando de PD-1 y una composición o kit que la comprende, su uso en la respuesta inmune, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845712P | 2013-07-12 | 2013-07-12 | |
PCT/JP2014/069122 WO2015005500A1 (en) | 2013-07-12 | 2014-07-11 | Virus like particle comprising pd-1 antigen or pd-1 ligand antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016000381A true MX2016000381A (es) | 2016-09-07 |
MX364952B MX364952B (es) | 2019-05-14 |
Family
ID=52277262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000381A MX364952B (es) | 2013-07-12 | 2014-07-11 | Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9637532B2 (es) |
EP (2) | EP3666890A1 (es) |
JP (1) | JP6557208B2 (es) |
KR (1) | KR20160029124A (es) |
CN (1) | CN105358683A (es) |
AR (1) | AR096885A1 (es) |
AU (1) | AU2014288147B2 (es) |
BR (1) | BR112016000303A2 (es) |
CA (1) | CA2916458A1 (es) |
IL (1) | IL243304B (es) |
MX (1) | MX364952B (es) |
TW (1) | TWI676636B (es) |
WO (1) | WO2015005500A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013122262A1 (en) | 2012-02-16 | 2013-08-22 | Vlp Therapeutics, Llc | Virus like particle composition |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
KR20200029627A (ko) | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
US10660948B2 (en) * | 2015-03-18 | 2020-05-26 | Omnicyte | Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof |
US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
US11447550B2 (en) | 2016-10-04 | 2022-09-20 | The Curators Of The University Of Missouri | Peptides for molecular detection of PD-L1 |
JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規pd-l1標的dnaワクチン |
ES2963635T3 (es) * | 2017-03-28 | 2024-04-01 | Ohio State Innovation Foundation | Vacunas de péptido PD1 humano y usos de las mismas |
CA3090552A1 (en) * | 2018-02-07 | 2019-08-15 | Imugene Limited | A vaccine composition and uses thereof |
FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
WO2019173223A1 (en) * | 2018-03-05 | 2019-09-12 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
WO2020071869A1 (ko) * | 2018-10-05 | 2020-04-09 | 알엔에이진 주식회사 | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 |
US20220064259A1 (en) * | 2019-01-04 | 2022-03-03 | George Mason Research Foundation, Inc. | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
CN111116733B (zh) * | 2019-11-28 | 2021-11-05 | 广东药科大学 | 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体 |
CN115175924A (zh) * | 2020-02-26 | 2022-10-11 | 港大科桥有限公司 | 基于pd-1的针对冠状病毒感染的疫苗 |
WO2024111633A1 (ja) * | 2022-11-24 | 2024-05-30 | 国立大学法人徳島大学 | タンパク質に対する抗体の作製 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
ES2129461T3 (es) | 1991-11-16 | 1999-06-16 | Smithkline Beecham Biolog | Proteina hibrida entre cs de plasmodium y hbsag. |
US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
CA2232669A1 (en) | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
JP2002507393A (ja) | 1998-02-11 | 2002-03-12 | マキシジェン, インコーポレイテッド | 抗原ライブラリー免疫 |
WO2001014557A1 (en) * | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
US20110262389A1 (en) | 2001-02-13 | 2011-10-27 | Mosca Joseph D | Tumor-derived Biological Antigen Presenting Particles |
JP4080423B2 (ja) | 2001-05-30 | 2008-04-23 | トランジェーヌ、ソシエテ、アノニム | アデノウイルスタンパク質ix、ならびにキャプシドアセンブリー、転写活性および核再組織化に関与するそのドメイン |
US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
EP1572941A4 (en) | 2002-02-26 | 2009-03-18 | Maxygen Inc | NEW FLAVIVIRUS ANTIGENES |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
AU2003295470A1 (en) | 2002-11-13 | 2004-06-03 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
DK3246399T3 (da) | 2002-12-13 | 2021-10-04 | Alphavax Inc | Alfavirus-partikler og fremgangsmåder til fremstilling |
KR101454842B1 (ko) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
CA2527636A1 (en) | 2003-05-29 | 2005-01-06 | United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A | Live attenuated viral vaccines for eastern equine encephalitis virus |
MXPA06006221A (es) * | 2003-12-01 | 2008-02-13 | Dow Global Technologies Inc | Produccion de particula tipo virus icosaedrico recombinante en organismos del genero pseudomonas. |
DE602005012382D1 (de) * | 2004-05-18 | 2009-03-05 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
WO2006040334A1 (en) | 2004-10-14 | 2006-04-20 | Crucell Holland B.V. | Malaria prime/boost vaccines |
EP1849799A4 (en) | 2005-02-16 | 2009-05-20 | Tokyo Inst Tech | MODIFIED VIRUS CAPSID PROTEIN AND APPLICATION THEREOF |
KR101600225B1 (ko) * | 2005-06-08 | 2016-03-04 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
EP1997887B1 (en) | 2006-03-03 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
US7499304B2 (en) | 2006-07-31 | 2009-03-03 | Sandisk 3D Llc | Systems for high bandwidth one time field-programmable memory |
US20100120092A1 (en) | 2006-08-30 | 2010-05-13 | Hepgenics Pty Ltd. | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
GB2453155A (en) | 2007-09-26 | 2009-04-01 | Rolls Royce Plc | Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine |
US20110035004A1 (en) | 2007-11-14 | 2011-02-10 | Maxwell G | Interfaced medical implant |
CA2705787A1 (en) | 2007-11-26 | 2009-06-25 | Novartis Ag | Methods of generating alphavirus particles |
MY161495A (en) * | 2008-11-26 | 2017-04-14 | Government Of The Us Secretary Dept Of Health And Human Services | Virus like particle compositions and methods of use |
US20120219579A1 (en) | 2009-09-18 | 2012-08-30 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
JP5600741B2 (ja) | 2010-07-13 | 2014-10-01 | 帝人株式会社 | 炭素繊維束及びその製造方法、ならびにそれからの成形品 |
WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
US9844588B2 (en) | 2011-06-17 | 2017-12-19 | Bharat Biotech International Limited | Inactivated chikungunya viruses (CHIKV) comprising an E1-K211E mutation |
EP2731961A4 (en) | 2011-07-12 | 2015-12-09 | Us Government | IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF |
CN102321639B (zh) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
HUE059406T2 (hu) * | 2011-10-17 | 2022-11-28 | Io Biotech Aps | PD-L1 alapú immunterápia |
US20150265694A1 (en) | 2011-10-25 | 2015-09-24 | Florida Gulf Coast University Board Of Trustees | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
WO2013122262A1 (en) | 2012-02-16 | 2013-08-22 | Vlp Therapeutics, Llc | Virus like particle composition |
WO2013151764A1 (en) | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
PT2850431T (pt) * | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
AP2015008926A0 (en) | 2013-06-03 | 2015-12-31 | Vlp Therapeutics Llc | Malaria vaccine |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
EP3119801B1 (en) | 2014-03-18 | 2019-07-17 | Fraunhofer Gesellschaft zur Förderung der Angewand | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
EP3240567A2 (en) | 2014-12-31 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Novel multivalent nanoparticle-based vaccines |
CN107849558A (zh) | 2015-06-12 | 2018-03-27 | 国立大学法人三重大学 | 2型人副流感病毒载体和疫苗 |
WO2016210127A1 (en) | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
MY187459A (en) | 2015-07-16 | 2021-09-23 | Bharat Biotech Int Ltd | Vaccine compositions |
WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
WO2017150683A1 (en) | 2016-03-04 | 2017-09-08 | Vlp Therapeutics, Llc | Zika virus virus like particle |
CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2014
- 2014-07-10 US US14/328,268 patent/US9637532B2/en active Active
- 2014-07-10 TW TW103123759A patent/TWI676636B/zh not_active IP Right Cessation
- 2014-07-11 AU AU2014288147A patent/AU2014288147B2/en not_active Expired - Fee Related
- 2014-07-11 EP EP19219213.6A patent/EP3666890A1/en not_active Withdrawn
- 2014-07-11 AR ARP140102570A patent/AR096885A1/es unknown
- 2014-07-11 CA CA2916458A patent/CA2916458A1/en not_active Abandoned
- 2014-07-11 CN CN201480039571.4A patent/CN105358683A/zh active Pending
- 2014-07-11 MX MX2016000381A patent/MX364952B/es active IP Right Grant
- 2014-07-11 EP EP14823398.4A patent/EP3019600B1/en active Active
- 2014-07-11 WO PCT/JP2014/069122 patent/WO2015005500A1/en active Application Filing
- 2014-07-11 BR BR112016000303A patent/BR112016000303A2/pt not_active Application Discontinuation
- 2014-07-11 KR KR1020167003373A patent/KR20160029124A/ko active Search and Examination
- 2014-07-11 JP JP2016501252A patent/JP6557208B2/ja active Active
-
2015
- 2015-12-23 IL IL243304A patent/IL243304B/en not_active IP Right Cessation
-
2017
- 2017-04-27 US US15/498,971 patent/US10464986B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10464986B2 (en) | 2019-11-05 |
CN105358683A (zh) | 2016-02-24 |
TWI676636B (zh) | 2019-11-11 |
EP3019600B1 (en) | 2019-12-25 |
WO2015005500A1 (en) | 2015-01-15 |
EP3666890A1 (en) | 2020-06-17 |
IL243304A0 (en) | 2016-03-31 |
TW201536812A (zh) | 2015-10-01 |
US20170233450A1 (en) | 2017-08-17 |
AR096885A1 (es) | 2016-02-03 |
IL243304B (en) | 2020-02-27 |
AU2014288147A1 (en) | 2016-01-21 |
BR112016000303A2 (pt) | 2017-12-12 |
KR20160029124A (ko) | 2016-03-14 |
CA2916458A1 (en) | 2015-01-15 |
MX364952B (es) | 2019-05-14 |
EP3019600A4 (en) | 2017-04-12 |
EP3019600A1 (en) | 2016-05-18 |
US9637532B2 (en) | 2017-05-02 |
US20150017194A1 (en) | 2015-01-15 |
AU2014288147B2 (en) | 2020-04-09 |
JP6557208B2 (ja) | 2019-08-07 |
JP2016526374A (ja) | 2016-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX364952B (es) | Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1. | |
IL268588A (en) | Anti-gprc5d antibodies, compositions comprising same and uses thereof | |
IL262497A (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
MX2022005173A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
MX2017009538A (es) | Antigenos de citomegalovirus y su uso. | |
MX357202B (es) | Composicion de particula tipo virus. | |
EP3558369A4 (en) | ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
IL247221B (en) | Antibodies that bind to the dengue virus, preparations containing them and their uses | |
WO2016090327A3 (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
FR3021319B1 (fr) | Peptides, compositions les comprenant et utilisations notamment cosmetiques | |
EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
MX2017011281A (es) | Conjugados de amatoxina y anticuerpos. | |
MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
EP4324518A3 (en) | Antibody molecules to tim-3 and uses thereof | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
WO2014144865A3 (en) | Anti-crth2 antibodies and their use | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
EP3021868A4 (en) | Antibodies against chikungunya virus and uses thereof | |
ZA201901892B (en) | Antibodies that bind interleukin-2 and uses thereof | |
IL265383A (en) | New antibodies against factor xi and their uses | |
IL247100A0 (en) | Antibodies against cd84, preparations containing them and their uses | |
IL237852A0 (en) | Antibodies against amphigoline, medical preparations containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |